Clin Lung Cancer 2017 Mar
Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Related Questions
New comment by Radiation Oncologist at University of Texas at Tyler ( April 7, 2023)
The esophagus is not a fixed structure and undergoes substantive, intrafractional peristalsis, hence how can its DVH be accurate over the course of treatment? Sekii et al., PM...
I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...
New comment by Radiation Oncologist at McMaster University School of Medicine ( March 15, 2023)
Interesting you ask...the data from LUSTRE that was presented at ASTRO 2022 does show a slight preponderance of grade 3 tox in patients treated with 60/8 vs 60/15 for central ...
New comment by Radiation Oncologist at Mon Health ( October 9, 2020)
Thank you.
What would be you field and margins?
New comment by Radiation Oncologist at Tennessee Oncology ( October 29, 2020)
@Matthew L. Mallory! Has been too long. I hope you are doing well. A thought-provoking question (what if level 5 or 6 only?)... I have to, of course, make several assumpt...